

POSTER PRESENTATION

Open Access

Targeting immune checkpoint pathways overcomes tumor-induced CD8+ T cell suppression

Lukas W Pfannenstiel*, Brian R Gastman

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

The immune system has the potential to be a powerful tool to destroy tumors. However despite ample evidence of anti-tumor immune responses in many patients, as well as years of immunotherapy development, truly effective immune-based therapies remain out of reach. We have previously shown that short-term *in vitro* co-culture of human T cells with human-derived tumor cell lines of various origins can induce the gain of senescence-like features in both CD4+ and CD8+ T cells, particularly the loss of CD27/CD28 expression. We found this tumor-induced senescence does not involve activation/proliferation, and also results in the gain of a potent suppressive function in *in vitro* suppression assays. In subsequent studies, we found that IL-7 could protect T cells from CD27/CD28 loss and acquisition of suppressive function and that this process is highly dependent on the expression of the anti-apoptotic protein Mcl-1.

In the current study we sought to determine whether a similar process could not only be found in mice, but also in tumor-resident T cells (TIL) collected from human patient specimens. We show that the process of tumor-induced dysfunction also induces the expression of PD-1 in both human and mouse T cells *in vitro*, and that tumor-exposed mouse T cells are also capable of suppressive function. Similar to published reports, we find tumor-resident human CD8+ TIL to have significant losses in CD27/CD28 expression, and that loss of these markers is accompanied by the gain in PD-1 expression, as well as other known checkpoint inhibitors, especially Tim-3. In mice, TIL also highly express PD-1, Tim-3, and Lag-3 but similar to *in vitro* studies, do not lose expression of CD27 and CD28. Using cell sorting to isolate CD3+ CD8+ PD-1 + Tim-3+ T cells from both mouse and human tumors, we find that this population is able to suppress autologous or syngeneic responder T cells in *ex vivo* proliferation

assays. We further show that use of antibody blockade of PD-1 and Tim-3 signaling *in vitro* and *in vivo* prevents the development of suppression. Ongoing studies will examine the signaling mechanisms responsible, especially by evaluating the role of Mcl-1 expression in generation of dysfunctional CD8 T cells *in vivo*. These studies demonstrate that tumor-derived factors can induce suppressive CD8+ T cells, and that blockade of negative regulators of T cell function can help prevent this process, indicating an additional benefit to the clinical use of these immunotherapies.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P119

Cite this article as: Pfannenstiel and Gastman: Targeting immune checkpoint pathways overcomes tumor-induced CD8+ T cell suppression. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P119.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Cleveland Clinic, Cleveland, OH, USA



© 2014 Pfannenstiel and Gastman; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.